KRAS is mutated in 3.3% of malignant solid tumor patients with KRAS Mutation present in 3.08% of all malignant solid tumor patients [4].

KRAS Mutation is an inclusion criterion in 35 clinical trials for malignant solid tumor, of which 29 are open and 6 are closed. Of the trials that contain KRAS Mutation and malignant solid tumor as inclusion criteria, 20 are phase 1 (14 open), 7 are phase 1/phase 2 (7 open), and 8 are phase 2 (8 open) [5].

Selumetinib, everolimus, and olaparib are the most frequent therapies in trials for malignant solid tumor that contain KRAS Mutation [5].

KRAS is mutated in 29.7% of non-small cell lung carcinoma patients with KRAS Mutation present in 29.05% of all non-small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 27 clinical trials for non-small cell lung carcinoma, of which 23 are open and 4 are closed. Of the trials that contain KRAS Mutation and non-small cell lung carcinoma as inclusion criteria, 11 are phase 1 (9 open), 4 are phase 1/phase 2 (4 open), 10 are phase 2 (8 open), and 2 are phase 3 (2 open) [5].

Pemetrexed, pembrolizumab, and erlotinib are the most frequent therapies in trials for non-small cell lung carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 47.01% of colorectal carcinoma patients with KRAS Mutation present in 47.01% of all colorectal carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 17 clinical trials for colorectal carcinoma, of which 16 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal carcinoma as inclusion criteria, 9 are phase 1 (8 open), 6 are phase 1/phase 2 (6 open), and 2 are phase 2 (2 open) [5].

Trametinib, cetuximab, and asn007 are the most frequent therapies in trials for colorectal carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 3.77% of acute myeloid leukemia patients with KRAS Mutation present in 3.77% of all acute myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 7 clinical trials for acute myeloid leukemia, of which 6 are open and 1 is closed. Of the trials that contain KRAS Mutation and acute myeloid leukemia as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (2 open), and 2 are phase 2 (2 open) [5].

Allogeneic hematopoietic stem cell transplantation, busulfan, and fludarabine are the most frequent therapies in trials for acute myeloid leukemia that contain KRAS Mutation [5].

KRAS is mutated in 86.05% of pancreatic carcinoma patients with KRAS Mutation present in 85.75% of all pancreatic carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for pancreatic carcinoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic carcinoma as inclusion criteria, 2 are phase 1 (2 open), 3 are phase 1/phase 2 (3 open), and 1 is phase 2 (1 open) [5].

Extended release flucytosine, trail receptor agonist abbv-621, and valproic acid are the most frequent therapies in trials for pancreatic carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 3.6% of non-hodgkin lymphoma patients with KRAS Mutation present in 3.6% of all non-hodgkin lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 6 clinical trials for non-hodgkin lymphoma, of which 6 are open and 0 are closed. Of the trials that contain KRAS Mutation and non-hodgkin lymphoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 4 are phase 2 (4 open) [5].

Ulixertinib, selumetinib, and antineoplastic immune cell are the most frequent therapies in trials for non-hodgkin lymphoma that contain KRAS Mutation [5].

KRAS is mutated in 3.03% of melanoma patients with KRAS Mutation present in 2.51% of all melanoma patients [4].

KRAS Mutation is an inclusion criterion in 5 clinical trials for melanoma, of which 4 are open and 1 is closed. Of the trials that contain KRAS Mutation and melanoma as inclusion criteria, 4 are phase 1 (3 open) and 1 is phase 1/phase 2 (1 open) [5].

Asn007, erk1/2 inhibitor ly3214996, and extended release flucytosine are the most frequent therapies in trials for melanoma that contain KRAS Mutation [5].

KRAS is mutated in 1.35% of myelodysplastic syndromes patients with KRAS Mutation present in 1.35% of all myelodysplastic syndromes patients [4].

KRAS Mutation is an inclusion criterion in 5 clinical trials for myelodysplastic syndromes, of which 4 are open and 1 is closed. Of the trials that contain KRAS Mutation and myelodysplastic syndromes as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 2 are phase 2 (2 open) [5].

Allogeneic hematopoietic stem cell transplantation, busulfan, and fludarabine are the most frequent therapies in trials for myelodysplastic syndromes that contain KRAS Mutation [5].

KRAS is mutated in 1.92% of breast carcinoma patients with KRAS Mutation present in 0.76% of all breast carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 5 clinical trials for breast carcinoma, of which 5 are open and 0 are closed. Of the trials that contain KRAS Mutation and breast carcinoma as inclusion criteria, 3 are phase 1 (3 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Extended release flucytosine, vistusertib, and abemaciclib are the most frequent therapies in trials for breast carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 12.0% of chronic myelomonocytic leukemia patients with KRAS Mutation present in 12.0% of all chronic myelomonocytic leukemia patients [4].

KRAS Mutation is an inclusion criterion in 4 clinical trials for chronic myelomonocytic leukemia, of which 3 are open and 1 is closed. Of the trials that contain KRAS Mutation and chronic myelomonocytic leukemia as inclusion criteria, 1 is phase 1 (1 open), 2 are phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Busulfan, fludarabine, and allogeneic cd56-positive cd3-negative natural killer cells are the most frequent therapies in trials for chronic myelomonocytic leukemia that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 4 clinical trials for multiple myeloma, of which 4 are open and 0 are closed. Of the trials that contain KRAS Mutation and multiple myeloma as inclusion criteria, 2 are phase 1 (2 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Antineoplastic immune cell, raf/mek serine/threonine kinase inhibitor ro5126766, and abemaciclib are the most frequent therapies in trials for multiple myeloma that contain KRAS Mutation [5].

KRAS is mutated in 80.0% of pancreatic ductal adenocarcinoma patients with KRAS Mutation present in 80.0% of all pancreatic ductal adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for pancreatic ductal adenocarcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and pancreatic ductal adenocarcinoma as inclusion criteria, 2 are phase 1 (2 open) and 1 is phase 2 (1 open) [5].

Asn007, erk1/2 inhibitor ly3214996, and abemaciclib are the most frequent therapies in trials for pancreatic ductal adenocarcinoma that contain KRAS Mutation [5].

KRAS is mutated in 44.19% of colorectal adenocarcinoma patients with KRAS Mutation present in 43.74% of all colorectal adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for colorectal adenocarcinoma, of which 2 are open and 1 is closed. Of the trials that contain KRAS Mutation and colorectal adenocarcinoma as inclusion criteria, 1 is phase 1 (0 open), 1 is phase 2 (1 open), and 1 is phase 3 (1 open) [5].

Anti-gpa33/cd3 monoclonal antibody mgd007, vitamin c supplement, and dexamethasone are the most frequent therapies in trials for colorectal adenocarcinoma that contain KRAS Mutation [5].

KRAS is mutated in 11.36% of ovarian carcinoma patients with KRAS Mutation present in 11.36% of all ovarian carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for ovarian carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and ovarian carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 2 are phase 1/phase 2 (2 open) [5].

Extended release flucytosine, sra737, and vistusertib are the most frequent therapies in trials for ovarian carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 9.87% of acute lymphoblastic leukemia patients with KRAS Mutation present in 9.87% of all acute lymphoblastic leukemia patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for acute lymphoblastic leukemia, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and acute lymphoblastic leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 2 are phase 2 (2 open) [5].

Antineoplastic immune cell, ect-001 expanded cord blood, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for acute lymphoblastic leukemia that contain KRAS Mutation [5].

KRAS is mutated in 2.38% of head and neck squamous cell carcinoma patients with KRAS Mutation present in 1.65% of all head and neck squamous cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for head and neck squamous cell carcinoma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and head and neck squamous cell carcinoma as inclusion criteria, 1 is phase 1 (1 open), 1 is phase 1/phase 2 (1 open), and 1 is phase 2 (1 open) [5].

Ko-947 and sra737 are the most frequent therapies in trials for head and neck squamous cell carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 0.81% of glioma patients with KRAS Mutation present in 0.81% of all glioma patients [4].

KRAS Mutation is an inclusion criterion in 3 clinical trials for glioma, of which 3 are open and 0 are closed. Of the trials that contain KRAS Mutation and glioma as inclusion criteria, 3 are phase 1/phase 2 (3 open) [5].

Cobimetinib and trametinib are the most frequent therapies in trials for glioma that contain KRAS Mutation [5].

KRAS is mutated in 43.13% of colon carcinoma patients with KRAS Mutation present in 42.51% of all colon carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for colon carcinoma, of which 1 is open and 1 is closed. Of the trials that contain KRAS Mutation and colon carcinoma as inclusion criteria, 1 is phase 1 (0 open) and 1 is phase 1/phase 2 (1 open) [5].

Valproic acid and neratinib are the most frequent therapies in trials for colon carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 32.99% of lung adenocarcinoma patients with KRAS Mutation present in 32.35% of all lung adenocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for lung adenocarcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and lung adenocarcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) and 1 is phase 2 (1 open) [5].

Ponatinib and trametinib are the most frequent therapies in trials for lung adenocarcinoma that contain KRAS Mutation [5].

KRAS is mutated in 6.76% of bladder carcinoma patients with KRAS Mutation present in 6.02% of all bladder carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for bladder carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and bladder carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for bladder carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 13.13% of esophageal carcinoma patients with KRAS Mutation present in 3.64% of all esophageal carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for esophageal carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and esophageal carcinoma as inclusion criteria, 2 are phase 2 (2 open) [5].

Palbociclib is the most frequent therapy in trials for esophageal carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 1.49% of diffuse large B-cell lymphoma patients with KRAS Mutation present in 1.49% of all diffuse large B-cell lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for diffuse large B-cell lymphoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and diffuse large B-cell lymphoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 2 (1 open) [5].

Antineoplastic immune cell, trail receptor agonist abbv-621, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for diffuse large B-cell lymphoma that contain KRAS Mutation [5].

KRAS is mutated in 1.07% of renal cell carcinoma patients with KRAS Mutation present in 1.07% of all renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for renal cell carcinoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

Vistusertib, cabozantinib, and docetaxel are the most frequent therapies in trials for renal cell carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 0.93% of neuroblastoma patients with KRAS Mutation present in 0.93% of all neuroblastoma patients [4].

KRAS Mutation is an inclusion criterion in 2 clinical trials for neuroblastoma, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and neuroblastoma as inclusion criteria, 1 is phase 1 (1 open) and 1 is phase 1/phase 2 (1 open) [5].

Cobimetinib is the most frequent therapy in trials for neuroblastoma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 2 clinical trials for neurofibromatosis type 1, of which 2 are open and 0 are closed. Of the trials that contain KRAS Mutation and neurofibromatosis type 1 as inclusion criteria, 2 are phase 1/phase 2 (2 open) [5].

Trametinib is the most frequent therapy in trials for neurofibromatosis type 1 that contain KRAS Mutation [5].

KRAS is mutated in 20.89% of endometrial carcinoma patients with KRAS Mutation present in 20.0% of all endometrial carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for endometrial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and endometrial carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Vistusertib and selumetinib are the most frequent therapies in trials for endometrial carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 16.45% of cholangiocarcinoma patients with KRAS Mutation present in 15.87% of all cholangiocarcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for cholangiocarcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and cholangiocarcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Vistusertib, adavosertib, and capivasertib are the most frequent therapies in trials for cholangiocarcinoma that contain KRAS Mutation [5].

KRAS is mutated in 11.93% of lung carcinoma patients with KRAS Mutation present in 11.35% of all lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Vitamin c supplement is the most frequent therapy in trials for lung carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 11.95% of malignant ovarian epithelial tumor patients with KRAS Mutation present in 8.37% of all malignant ovarian epithelial tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant ovarian epithelial tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant ovarian epithelial tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

Paclitaxel and spleen tyrosine kinase inhibitor tak-659 are the most frequent therapies in trials for malignant ovarian epithelial tumor that contain KRAS Mutation [5].

KRAS is mutated in 11.87% of gastric carcinoma patients with KRAS Mutation present in 7.99% of all gastric carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gastric carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gastric carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Palbociclib is the most frequent therapy in trials for gastric carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 6.57% of cancer patients with KRAS Mutation present in 6.57% of all cancer patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for cancer, of which 0 are open and 1 is closed. Of the trial that contains KRAS Mutation and cancer as inclusion criteria, 1 is phase 1 (0 open) [5].

KRAS is mutated in 16.67% of germ cell tumor patients with KRAS Mutation present in 5.56% of all germ cell tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for germ cell tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and germ cell tumor as inclusion criteria, 1 is phase 2 (1 open) [5].

Palbociclib is the most frequent therapy in trials for germ cell tumor that contain KRAS Mutation [5].

KRAS is mutated in 6.22% of urothelial carcinoma patients with KRAS Mutation present in 5.47% of all urothelial carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for urothelial carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and urothelial carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is mutated in 5.03% of thyroid gland carcinoma patients with KRAS Mutation present in 5.03% of all thyroid gland carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Vistusertib and selumetinib are the most frequent therapies in trials for thyroid gland carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 5.0% of malignant peripheral nerve sheath tumor patients with KRAS Mutation present in 5.0% of all malignant peripheral nerve sheath tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for malignant peripheral nerve sheath tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and malignant peripheral nerve sheath tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Cobimetinib is the most frequent therapy in trials for malignant peripheral nerve sheath tumor that contain KRAS Mutation [5].

KRAS is mutated in 5.35% of squamous cell lung carcinoma patients with KRAS Mutation present in 4.53% of all squamous cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for squamous cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and squamous cell lung carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Vistusertib and selumetinib are the most frequent therapies in trials for squamous cell lung carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 4.31% of papillary renal cell carcinoma patients with KRAS Mutation present in 4.31% of all papillary renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for papillary renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and papillary renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for papillary renal cell carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 4.31% of poorly differentiated thyroid gland carcinoma patients with KRAS Mutation present in 4.31% of all poorly differentiated thyroid gland carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for poorly differentiated thyroid gland carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and poorly differentiated thyroid gland carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in trials for poorly differentiated thyroid gland carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 3.7% of mantle cell lymphoma patients with KRAS Mutation present in 3.7% of all mantle cell lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for mantle cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and mantle cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for mantle cell lymphoma that contain KRAS Mutation [5].

KRAS is mutated in 3.97% of small cell lung carcinoma patients with KRAS Mutation present in 3.4% of all small cell lung carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for small cell lung carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and small cell lung carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in trials for small cell lung carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 4.31% of rhabdomyosarcoma patients with KRAS Mutation present in 2.59% of all rhabdomyosarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdomyosarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdomyosarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Cobimetinib is the most frequent therapy in trials for rhabdomyosarcoma that contain KRAS Mutation [5].

KRAS is mutated in 2.44% of histiocytic and dendritic cell neoplasm patients with KRAS Mutation present in 2.44% of all histiocytic and dendritic cell neoplasm patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for histiocytic and dendritic cell neoplasm, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and histiocytic and dendritic cell neoplasm as inclusion criteria, 1 is phase 2 (1 open) [5].

Selumetinib is the most frequent therapy in trials for histiocytic and dendritic cell neoplasm that contain KRAS Mutation [5].

KRAS is mutated in 2.15% of thyroid gland follicular carcinoma patients with KRAS Mutation present in 2.15% of all thyroid gland follicular carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland follicular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland follicular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in trials for thyroid gland follicular carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 2.02% of thyroid gland papillary carcinoma patients with KRAS Mutation present in 2.02% of all thyroid gland papillary carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thyroid gland papillary carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thyroid gland papillary carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Thyroid stimulating hormone [epc], dabrafenib, and trametinib are the most frequent therapies in trials for thyroid gland papillary carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 1.64% of lymphoma patients with KRAS Mutation present in 1.64% of all lymphoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and lymphoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for lymphoma that contain KRAS Mutation [5].

KRAS is mutated in 1.87% of sarcoma patients with KRAS Mutation present in 1.53% of all sarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and sarcoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for sarcoma that contain KRAS Mutation [5].

KRAS is mutated in 1.47% of chronic myeloid leukemia patients with KRAS Mutation present in 1.47% of all chronic myeloid leukemia patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for chronic myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and chronic myeloid leukemia as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Allogeneic cd56-positive cd3-negative natural killer cells, interleukin-2, and allogeneic hematopoietic stem cell transplantation are the most frequent therapies in trials for chronic myeloid leukemia that contain KRAS Mutation [5].

KRAS is mutated in 1.85% of soft tissue sarcoma patients with KRAS Mutation present in 1.15% of all soft tissue sarcoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for soft tissue sarcoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and soft tissue sarcoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Cobimetinib is the most frequent therapy in trials for soft tissue sarcoma that contain KRAS Mutation [5].

KRAS is mutated in 1.67% of glioblastoma patients with KRAS Mutation present in 1.04% of all glioblastoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for glioblastoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and glioblastoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for glioblastoma that contain KRAS Mutation [5].

KRAS is mutated in 2.06% of head and neck carcinoma patients with KRAS Mutation present in 0.92% of all head and neck carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for head and neck carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and head and neck carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for head and neck carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 1.1% of prostate carcinoma patients with KRAS Mutation present in 0.87% of all prostate carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for prostate carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and prostate carcinoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Sra737 is the most frequent therapy in trials for prostate carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 0.68% of gastrointestinal stromal tumor patients with KRAS Mutation present in 0.68% of all gastrointestinal stromal tumor patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for gastrointestinal stromal tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and gastrointestinal stromal tumor as inclusion criteria, 1 is phase 1 (1 open) [5].

Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for gastrointestinal stromal tumor that contain KRAS Mutation [5].

KRAS is mutated in 0.63% of hepatocellular carcinoma patients with KRAS Mutation present in 0.63% of all hepatocellular carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for hepatocellular carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and hepatocellular carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

KRAS is mutated in 0.16% of clear cell renal cell carcinoma patients with KRAS Mutation present in 0.16% of all clear cell renal cell carcinoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for clear cell renal cell carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and clear cell renal cell carcinoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for clear cell renal cell carcinoma that contain KRAS Mutation [5].

KRAS is mutated in 2.99% of anaplastic astrocytoma patients [4].

KRAS Mutation is an inclusion criterion in 1 clinical trial for anaplastic astrocytoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and anaplastic astrocytoma as inclusion criteria, 1 is phase 1 (1 open) [5].

Extended release flucytosine and vocimagene amiretrorepvec are the most frequent therapies in trials for anaplastic astrocytoma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for double-hit lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and double-hit lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for double-hit lymphoma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for myelodysplastic/myeloproliferative neoplasm, unclassifiable, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and myelodysplastic/myeloproliferative neoplasm, unclassifiable as inclusion criteria, 1 is phase 1 (1 open) [5].

Busulfan, fludarabine, and venetoclax are the most frequent therapies in trials for myelodysplastic/myeloproliferative neoplasm, unclassifiable that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peripheral T-cell lymphoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peripheral T-cell lymphoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Antineoplastic immune cell, allogeneic hematopoietic stem cell transplantation, and autologous hematopoietic stem cell transplatation are the most frequent therapies in trials for peripheral T-cell lymphoma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for peritoneal mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and peritoneal mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for peritoneal mesothelioma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for pleural mesothelioma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and pleural mesothelioma as inclusion criteria, 1 is phase 1 (1 open) [5].

Cabozantinib, docetaxel, and erlotinib are the most frequent therapies in trials for pleural mesothelioma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for refractory anemia with excess blasts-2, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and refractory anemia with excess blasts-2 as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Binimetinib is the most frequent therapy in trials for refractory anemia with excess blasts-2 that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for rhabdoid tumor, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and rhabdoid tumor as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Cobimetinib is the most frequent therapy in trials for rhabdoid tumor that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for schwannoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and schwannoma as inclusion criteria, 1 is phase 1/phase 2 (1 open) [5].

Cobimetinib is the most frequent therapy in trials for schwannoma that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for secondary acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and secondary acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Ect-001 expanded cord blood is the most frequent therapy in trials for secondary acute myeloid leukemia that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for therapy-related acute myeloid leukemia, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and therapy-related acute myeloid leukemia as inclusion criteria, 1 is phase 2 (1 open) [5].

Ect-001 expanded cord blood is the most frequent therapy in trials for therapy-related acute myeloid leukemia that contain KRAS Mutation [5].

KRAS Mutation is an inclusion criterion in 1 clinical trial for thymic carcinoma, of which 1 is open and 0 are closed. Of the trial that contains KRAS Mutation and thymic carcinoma as inclusion criteria, 1 is phase 2 (1 open) [5].

Akt inhibitor mk2206, erlotinib, and lapatinib are the most frequent therapies in trials for thymic carcinoma that contain KRAS Mutation [5].